# A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

> **NCT03227224** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 287 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-42847922

## Key facts

- **NCT ID:** NCT03227224
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2019-01-12
- **Final completion:** 2019-01-19
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227224, "A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03227224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*